Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -237.77% | 43.66% | 34.84% | 3.29% | 28.49% |
| Total Depreciation and Amortization | -0.75% | -3.96% | 0.74% | -43.85% | 70.62% |
| Total Amortization of Deferred Charges | 0.00% | 1,879.44% | -200.00% | -- | -- |
| Total Other Non-Cash Items | 418.73% | -220.46% | -31.31% | 348.12% | -129.34% |
| Change in Net Operating Assets | -219.07% | 146.12% | -101.97% | -477.87% | 116.10% |
| Cash from Operations | 4.84% | 48.67% | 0.73% | 24.62% | -23.07% |
| Capital Expenditure | 54.38% | -733.52% | 59.73% | 52.67% | 32.94% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 62.48% | -44.29% | -24.21% | -102.48% | 64.96% |
| Cash from Investing | 58.38% | -148.87% | 5.59% | 6.55% | 47.26% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -600.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -100.00% | -99.56% | 1,783.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 92.71% | -- | -- | -- |
| Cash from Financing | 268.59% | -101.01% | 1,819.94% | -104.68% | 1,783.46% |
| Foreign Exchange rate Adjustments | -224.30% | 222.06% | -1,303.45% | 105.88% | -526.84% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.27% | -157.18% | 187.82% | -199.18% | 216.19% |